The bottleneck is inside and being paid away

scPharmaceuticals Inc. (SCPH) — this company's answers

The model's full reasoning — Q3 2023 call → NOWe need to answer YES or NO based solely on the transcript. The question: does management convey that the main thing standing between the company and meaningfully more business right now is the company's own capability (capacity, people, facilities, throughput, ability to deliver) rather than a shortage of demand, AND that the company is already spending real money and effort to remove that internal limit, with the business waiting on the other side already visible today? Essentially, is there a situation where demand exceeds supply capability, and the company is actively expanding to meet it? We need to check the transcript. The company is launching FUROSCIX. They added 12 sales territories at the end of Q3. They talk about demand growing, prescriptions, etc. They also mention adding a specialty pharmacy to their network to maximize access. They talk about payer agreements to increase access. But the question is about internal capability being the constraint. Is there any indication that they cannot fulfill demand due to their own capacity? They mention adding territories to increase sales force, but that's more about generating demand, not about fulfilling orders. They mention adding a specialty pharmacy to maximize access in states requiring waiver - so that's about distribution capacity. They mention that they have a field sales force of 66 territories and plan to add more. But is that about reaching more doctors, not about inability to serve existing demand? The question asks: "the main thing standing between the company and meaningfully more business right now is the company's own capability — its capacity, people, facilities, throughput, or ability to deliver — rather than a shortage of demand." From the transcript, they talk about demand growing, and they are adding sales territories to capture more demand. But that suggests they are expanding their sales capacity to go after more demand, but is there a backorder or waiting buyers? They talk about pending prescriptions, but that's about payer approval, not about company capacity. They also talk about fill rate increasing. There is no mention of production capacity or inability to deliver product. They have inventory levels consistent. They say they added 12 territories to increase sales force, but that's about reaching more doctors, not about serving existing customers.

← Back to the full SCPH analysis